VX-702

For research use only.

Catalog No.S6005

31 publications

VX-702 Chemical Structure

CAS No. 745833-23-2

VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.

Selleck's VX-702 has been cited by 31 publications

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.
Features Highly selective, orally active inhibitor of p38 MAPK.
Targets
p38α [1]
(Cell-free assay)
4 nM-20 nM
In vitro

Pre-incubation of platelets with VX-702 (1 μM) completely or partially inhibits p38 activation (IC50 4 to 20 nM) induced by platelet agonists including thrombin, SFLLRN, AYPGKF, U46619 and collagen. VX-702 shows no effect on platelet aggregation induced by any of the p38 MAPK agonists in the presence or absence of anti-platelet therapies. [1] VX-702 inhibits the production of IL-6, IL-1β and TNFα (IC50 = 59, 122 and 99 ng/mL, respectively) in a dose-dependent manner. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HOP-62 cell NEPydpNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnjsTY5pcWKrdHnvckBw\iCqdX3hckBJV1BvNkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlAyPTR|IN88US=> MVnTRW5ITVJ?
human NCI-H720 cell MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUO3XXVMUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFczOCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMEG2PFIh|ryP MX\TRW5ITVJ?
JVM-2 cell NFm0bXVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVPEZ3lbUW6qaXLpeIlwdiCxZjDoeY1idiCMVl2tNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODh|IN88US=> NUTzO4FXW0GQR1XS
human NCI-H69 cell NVjKb4VuT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NICzbpRKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOlkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjB7OUSxJO69VQ>? NXz5[IpwW0GQR1XS
human BV-173 cell MmfVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH\QUmtKdmirYnn0bY9vKG:oIHj1cYFvKEKYLUG3N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTF|OE[g{txO NUjXd5QyW0GQR1XS
human KU812 cell MorSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MULJcohq[mm2aX;uJI9nKGi3bXHuJGtWQDF{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xNlQ5QCEQvF2= NVfOcYNrW0GQR1XS
human DU-145 cell MkWzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUDJcohq[mm2aX;uJI9nKGi3bXHuJGRWNTF2NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVQ2PTRizszN M{e5dXNCVkeHUh?=
KARPAS-45 cell NWKzVWdlT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3jrd2lvcGmkaYTpc44hd2ZiaIXtZY4hU0GUUFHTMVQ2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zNEiyOkDPxE1? MmPNV2FPT0WU
human AGS cell Ml[5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUXLeWNOUW6qaXLpeIlwdiCxZjDoeY1idiCDR2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE2OjVzIN88US=> NIXHN|FUSU6JRWK=
human MOLT-13 cell NX7YUpRST3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4HteGlvcGmkaYTpc44hd2ZiaIXtZY4hVU:OVD2xN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTV7OEGg{txO M4nmRXNCVkeHUh?=
human NCI-H209 cell M2r4XGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2LVb2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF5NUig{txO M1vjW3NCVkeHUh?=
human CTV-1 cell MknoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{HxVGlvcGmkaYTpc44hd2ZiaIXtZY4hS1SYLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE5Ozh7IN88US=> NF65U4FUSU6JRWK=
LU-139 cell MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIPEN3JKdmirYnn0bY9vKG:oIHj1cYFvKEyXLUGzPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTl2M{Wg{txO MmHNV2FPT0WU
ML-2 cell NV;TXWcyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Ml[2TY5pcWKrdHnvckBw\iCqdX3hckBOVC1{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yNlY3OSEQvF2= MVrTRW5ITVJ?
human K5 cell NGLwXpJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnLYTY5pcWKrdHnvckBw\iCqdX3hckBMPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMkK5NVch|ryP MnPDV2FPT0WU
human SBC-1 cell NXvwUoh4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVXJcohq[mm2aX;uJI9nKGi3bXHuJHNDSy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yN|YzKM7:TR?= NF3KXHRUSU6JRWK=
human COR-L88 cell M3j3R2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUPJcohq[mm2aX;uJI9nKGi3bXHuJGNQWi2OOEigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM{PDhizszN M3zNNnNCVkeHUh?=
human KY821 cell M4nYWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWL6[WV1UW6qaXLpeIlwdiCxZjDoeY1idiCNWUiyNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzl4MEOg{txO MkjJV2FPT0WU
human HCC2218 cell NYXHN4o{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFrvWmVKdmirYnn0bY9vKG:oIHj1cYFvKEiFQ{KyNVgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjR7N{K4JO69VQ>? MVrTRW5ITVJ?
human ECC10 cell M1;IVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEHlWmRKdmirYnn0bY9vKG:oIHj1cYFvKEWFQ{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE43PTN6OTFOwG0> NWLYVGpwW0GQR1XS
human EW-3 cell M4jkPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXvJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLk[2OlEyKM7:TR?= Mnn0V2FPT0WU
human EW-18 cell NYG4TmVlT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWLJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTF6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD63OFY4QSEQvF2= Mk\HV2FPT0WU
human UACC-257 cell NXjxT3BPT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFPGPYdKdmirYnn0bY9vKG:oIHj1cYFvKFWDQ1OtNlU4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5{MEOyOkDPxE1? NETsVYtUSU6JRWK=
human G-361 cell NWLpNGc3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1PQ[WlvcGmkaYTpc44hd2ZiaIXtZY4hTy1|NkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlQ6PTF7IN88US=> NGO4e2FUSU6JRWK=
human HMV-II cell NYrsdoJHT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M17KXGlvcGmkaYTpc44hd2ZiaIXtZY4hUE2YLVnJJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU44PzF6NDFOwG0> M1r6PXNCVkeHUh?=
human DEL cell MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlrlTY5pcWKrdHnvckBw\iCqdX3hckBFTUxiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkKwO|A1KM7:TR?= NYnUVJdIW0GQR1XS
human IGROV-1 cell MlLNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn\XTY5pcWKrdHnvckBw\iCqdX3hckBKT1KRVj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk41OzF6ODFOwG0> MV3TRW5ITVJ?
human SK-OV-3 cell MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NY[2[5ZzUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3PWk0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi54MU[5O{DPxE1? MofJV2FPT0WU
human LAMA-84 cell M{\jOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MV3Jcohq[mm2aX;uJI9nKGi3bXHuJGxCVUFvOESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlcyOjh2IN88US=> NXfFbFBUW0GQR1XS
human NCI-H510A cell M37FR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{KwZ2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi1NVBCKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi57MkWyOkDPxE1? MXzTRW5ITVJ?
human CP66-MEL cell NYXZWGRnT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXnleG1KUW6qaXLpeIlwdiCxZjDoeY1idiCFUE[2MW1GVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwOUO1OVkh|ryP MoPEV2FPT0WU
human HAL-01 cell M1n5WGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3[1S2lvcGmkaYTpc44hd2ZiaIXtZY4hUEGOLUCxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4zPzlzODFOwG0> NX\4dnp3W0GQR1XS
human RS4-11 cell  NUPKcXF3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVfG[5hYUW6qaXLpeIlwdiCxZjDoeY1idiCUU{StNVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjdyNUezJO69VQ>? NYDOSI5{W0GQR1XS
human RPMI-8226 cell NGnzWIFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MU\Jcohq[mm2aX;uJI9nKGi3bXHuJHJRVUlvOEKyOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQDJ|N{[g{txO M3TrNHNCVkeHUh?=
human NCI-H82 cell MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFrTemJKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IPFIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Njh7M{C1JO69VQ>? NFn6b2lUSU6JRWK=
human NY cells NGW0ZVVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlLzTY5pcWKrdHnvckBw\iCqdX3hckBPYSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwMke2N|ch|ryP NHHtd5lUSU6JRWK=
human MDA-MB-361 cell NWfBN4c2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnGzTY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtN|YyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC52M{G1PEDPxE1? MVjTRW5ITVJ?
human MOLT-4 cell NH;T[3NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnTiTY5pcWKrdHnvckBw\iCqdX3hckBOV0yWLUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlk6OTl|IN88US=> MoTBV2FPT0WU
human DU-4475 cell M3H1OWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkPXTY5pcWKrdHnvckBw\iCqdX3hckBFXS12NEe1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4xPTV4NTFOwG0> MUjTRW5ITVJ?
human ESS-1 cell M2jMNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGVUWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT6yPVE4QSEQvF2= MnTFV2FPT0WU
human NCI-H1299 cell MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkjETY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEGyPVkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjV|MEOzJO69VQ>? Ml7pV2FPT0WU
human COLO-684 cell NEjIb2hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV3Jcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vNki0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU42QDF4NTFOwG0> MmHCV2FPT0WU
human MV-4-11 cell NWK3S5BpT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlKyTY5pcWKrdHnvckBw\iCqdX3hckBOXi12LUGxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU44OTF7OTFOwG0> NHfHcGtUSU6JRWK=
human D-542MG cell MmT2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NV3EOnhTUW6qaXLpeIlwdiCxZjDoeY1idiCGLUW0Nm1IKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi5|OUK3NkDPxE1? M2K4cHNCVkeHUh?=
human A4-Fuk cell M1TOdWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4TvemlvcGmkaYTpc44hd2ZiaIXtZY4hSTRvRoXrJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok41OzZ4MjFOwG0> MWTTRW5ITVJ?
human HL-60 cell M3LwVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NE\hVmpKdmirYnn0bY9vKG:oIHj1cYFvKEiOLU[wJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{42OjJzMjFOwG0> MWjTRW5ITVJ?
human NCI-H526 cell NXO3WZE5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYS4[ZkzUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFUzPiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwNUm4NFEh|ryP MXPTRW5ITVJ?
human L-363 cell NV7VVHRDT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIHUS5pKdmirYnn0bY9vKG:oIHj1cYFvKExvM{[zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{44QTJ3MjFOwG0> NFWzeFJUSU6JRWK=
human A388 cell MljjS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVXJcohq[mm2aX;uJI9nKGi3bXHuJGE{QDhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15LkiwN|g1KM7:TR?= NGXCUXNUSU6JRWK=
human MS-1 MoTzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEnoV2hKdmirYnn0bY9vKG:oIHj1cYFvKE2VLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23Mlg{PDZ3IN88US=> M2\Xd3NCVkeHUh?=
human JAR cell MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGrTO2lKdmirYnn0bY9vKG:oIHj1cYFvKEqDUjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuPFQ6OjNizszN NVrucVRLW0GQR1XS
human TI-73 cell NUnSU2RCT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NX31UHdzUW6qaXLpeIlwdiCxZjDoeY1idiCWST23N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVgvODZ{MjFOwG0> NXfEZnRNW0GQR1XS
human CTB-1 cell M2LnTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mn\pTY5pcWKrdHnvckBw\iCqdX3hckBEXEJvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUiuNVc5OjVizszN MXXTRW5ITVJ?
human SK-NEP-1 cell MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIGxc2lKdmirYnn0bY9vKG:oIHj1cYFvKFONLV7FVE0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTFwM{CzPEDPxE1? MX;TRW5ITVJ?
human HT-29 cell NGqyXGxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mn\pTY5pcWKrdHnvckBw\iCqdX3hckBJXC1{OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGzMlkyOTFizszN MoL3V2FPT0WU
human NCI-H1092 cell MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1zNVWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixNFkzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTRwM{G4JO69VQ>? NYG0XGw3W0GQR1XS
human KMOE-2 cell MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2PHfWlvcGmkaYTpc44hd2ZiaIXtZY4hU02RRT2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVQvPjF5ODFOwG0> NIOzeHdUSU6JRWK=
human EM-2 cell NH;VdYtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NX62flljUW6qaXLpeIlwdiCxZjDoeY1idiCHTT2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVUvOjh2MTFOwG0> M4rldnNCVkeHUh?=
human RT-112 cell Mn3ES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIfK[pJKdmirYnn0bY9vKG:oIHj1cYFvKFKWLUGxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE2NjN7OESg{txO MUTTRW5ITVJ?
human DB cell M3e0ZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmL2TY5pcWKrdHnvckBw\iCqdX3hckBFSiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTF3Lki1NVMh|ryP MmriV2FPT0WU
human NCI-H1770 cell M2L0fmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIraW3dKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVc4OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7 NEDCTFVUSU6JRWK=
human CAL-54 cell NHnGOJBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mlj3TY5pcWKrdHnvckBw\iCqdX3hckBESUxvNUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOk44OyEQvF2= NF60XlJUSU6JRWK=
human NB14 cell MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml3JTY5pcWKrdHnvckBw\iCqdX3hckBPSjF2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUeuOlM6PSEQvF2= MlX0V2FPT0WU
human RPMI-7951 cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHrZXnNKdmirYnn0bY9vKG:oIHj1cYFvKFKSTVmtO|k2OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTF7LkG3PFMh|ryP MmPFV2FPT0WU
human T47D cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NY\qNmJRUW6qaXLpeIlwdiCxZjDoeY1idiCWNEfEJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlEvOjJ2MzFOwG0> MWfTRW5ITVJ?
human A549 cell NYH4cG9CT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnXRTY5pcWKrdHnvckBw\iCqdX3hckBCPTR7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkGuNlgyOSEQvF2= NH3mVJlUSU6JRWK=
human A2780 cell M3e5d2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUfJcohq[mm2aX;uJI9nKGi3bXHuJGEzPzhyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkGuPFIzPSEQvF2= NXnKdnNbW0GQR1XS
human SK-MEL-24 cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlvJTY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRVytNlQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Oy5yM{GxJO69VQ>? NW\ye|lCW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo The half-life of VX-702 is 16 to 20 hours, with a median clearance of 3.75 L/h and a volume of distribution of 73 L/kg. Both AUC and Cmax values are dose proportional for VX-702, which is predominantly cleared renally. [2] VX-702 (at a dose of 0.1 mg/kg twice daily) has an equivalent effect as that of methotrexate (0.1 mg/kg). In addition, VX-702 (5 mg/kg twice daily) also has an equivalent effect as prednisolone (10 mg/kg once daily), as measured by percentage inhibition of wrist joint erosion and inflammation score. [3] VX-702 selectively inhibits activation of p38 MAPK after ischemia with no effects on ERKs and JNKs. The MI/AAR ratio is significantly reduced in the 50 mg/kg group compared with the 5 mg/kg and vehicle groups.[4]

Protocol

Solubility (25°C)

In vitro DMSO 81 mg/mL (200.34 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+50% ddH2O
For best results, use promptly after mixing.
4 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 404.3
Formula

C19H12F4N4O2

CAS No. 745833-23-2
Storage powder
in solvent
Synonyms N/A
Smiles C1=CC(=C(C(=C1)F)N(C2=NC(=C(C=C2)C(=O)N)C3=C(C=C(C=C3)F)F)C(=O)N)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00395577 Completed Drug: VX-702 Rheumatoid Arthritis Vertex Pharmaceuticals Incorporated November 2006 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Related p38 MAPK Products

Tags: buy VX-702 | VX-702 supplier | purchase VX-702 | VX-702 cost | VX-702 manufacturer | order VX-702 | VX-702 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID